文献速递淋巴瘤

PET时代I/II期滤泡性淋巴瘤治疗结局:澳大利亚淋巴瘤联盟国际研究

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance.
PubMed 文献 · Blood Adv · 2019-01-01

中位随访45个月,各治疗策略总生存相似,单纯放疗与无维持全身治疗PFS相似,维持利妥昔单抗改善PFS,全身治疗降低转化风险。

要点

  • 早期FL中观察等待、放疗和全身治疗的总生存相似。
  • 维持利妥昔单抗可显著改善无进展生存(HR 0.24)。
  • 全身治疗较放疗或观察等待降低转化风险(HR 0.20)。

核心结论

  • 在现代PET分期时代,早期滤泡性淋巴瘤不同治疗策略均获得相似的优异总生存。
  • 维持利妥昔单抗与PFS改善相关,全身治疗与转化风险降低相关。

主要发现

  • 中位年龄63岁,I期221例;观察等待85例,积极治疗280例(单纯放疗171例、免疫化疗63例、联合模式治疗46例)。
  • I期患者72.7%接受单纯放疗,II期患者42.6%接受单纯放疗(P < .001)。
  • 积极治疗总缓解率相当(P = .87)。
  • 单纯放疗与无维持利妥昔单抗的全身治疗PFS相似(HR 1.32;95%CI 0.77-2.34;P = .96)。
  • 维持利妥昔单抗改善PFS(HR 0.24;95%CI 0.095-0.64;P = .017)。

关键数值与推荐

  • 单纯放疗与无维持全身治疗PFS的HR为1.32(95%CI 0.77-2.34;P = .96)。
  • 维持利妥昔单抗PFS的HR为0.24(95%CI 0.095-0.64;P = .017)。
  • 全身治疗转化风险的HR为0.20(95%CI 0.070-0.61;P = .034)。

临床怎么用

  • 早期FL治疗选择需个体化,观察等待、放疗和全身治疗均为合理选项。
  • 对接受全身治疗的患者,可考虑维持利妥昔单抗以改善PFS。
  • 全身治疗可能降低组织学转化风险,需与患者获益风险讨论。

局限性

  • 回顾性研究设计,治疗选择存在偏倚。
  • 需要随机研究确定早期FL的最佳治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management practices in early-stage (I/II) follicular lymphoma (FL) are variable and include radiation (RT), systemic therapy, or combined modality therapy (CMT). There is a paucity of data regarding maintenance rituximab in this cohort. We conducted an international retrospective study of patients with newly diagnosed early-stage FL staged with positron emission tomography (PET)-computed tomography and bone marrow biopsy. Three hundred sixty-five patients (stage I, n = 221), median age 63 years, treated from 2005-2017 were included, with a median follow-up of 45 months. Management included watchful waiting (WW; n = 85) and active treatment (n = 280). The latter consisted of RT alone (n = 171) or systemic therapy (immunochemotherapy [n = 63] or CMT [n = 46]). Forty-nine systemically treated patients received maintenance rituximab; 72.7% of stage I patients received RT alone, compared to 42.6% with stage II (P < .001). Active therapies yielded comparable overall response rates (P = .87). RT alone and systemic therapy without maintenance rituximab yielded similar progression-free survival (PFS) (hazard ratio [HR], 1.32; 95% confidence interval [CI], 0.77-2.34; P = .96). Maintenance rituximab improved PFS (HR, 0.24; 95% CI, 0.095-0.64; P = .017). The incidence of transformation was lower with systemic therapy compared to RT or WW (HR, 0.20; 95% CI, 0.070-0.61; P = .034). Overall survival was similar among all practices, including WW (P = .40). In the largest comparative assessment of management practices in the modern era, variable practices each resulted in similar excellent outcomes. Randomized studies are required to determine the optimal treatment in early-stage FL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tobin JWD, Rule G, Colvin K, et al. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Adv. 2019. PMID: 31570492. doi:10.1182/bloodadvances.2019000458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。